About Humacyte
Humacyte is a publicly listed company based in Morrisville (United States) founded in 2004. It operates as a human tissue-based products are developed for vascular disease applications. It operates on a HealthTech and Product-as-a-Service model. Humacyte has raised $424.76 million across 11 funding rounds from investors including SVB, Bangkok Bank and Fresenius Medical Care. The company has 220 employees. Its website humacyte.com draws about 12 thousand monthly visits. Humacyte offers products and services including Symvess™ and Acellular Tissue Engineered Vessel (ATEV™). Its focus areas include Biotechnology and Regenerative Medicine. Its legal entity is Humacyte Global, Inc. Its competitors include CUTISS, Solsys Medical, Heartseed, ORTHOCON and Tissue Regenix and 3 more; 6 of its 8 listed competitors have raised funding.
Company details
Humacyte is engaged in the development and manufacture of bioengineered human tissues and organs. These tissues are designed to be universally implantable, off-the-shelf, and regenerative, targeting a wide range of diseases, injuries, and chronic conditions. The companys platform supports tissue repair and replacement across various clinical needs, including vascular trauma, hemodialysis access, and investigational applications like tracheal and esophageal replacement. Solutions are built on the Acellular Tissue Engineered Vessel platform, aiming for low infection rates and broad patient accessibility in the healthcare sector.
- Headquarters Morrisville, United States
- Employees 220
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website humacyte.com
- Social LinkedIn Facebook
- Legal Name Humacyte, Inc.
- Annual Revenue$2.04 M (USD)0as on Dec 31, 2025
- Net Profit-$40.83 M (USD)72.54as on Dec 31, 2025
- EBITDA-$100.09 M (USD)6.64as on Dec 31, 2025
- Total Equity Funding$424.76M (USD)
in 11 rounds
- InvestorsSVB
& 12 more
- Employee Count220
Products & Services of Humacyte
Humacyte offers a comprehensive portfolio of products and services, including Symvess™ and Acellular Tissue Engineered Vessel (ATEV™).
Symvess™ is used for vascular trauma repair treatment.
ATEV™ is developed for hemodialysis arteriovenous access needs.
Funding Insights of Humacyte
Humacyte has successfully raised a total of $424.76M across 11 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $424.76M
- Total Rounds 11
- First Round $150,000
(Jun 2006)
- Investors Count 13
Latest 10 of 11 funding rounds of Humacyte with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2021 | – | Debt – Venture | – | – | |
| Jun 2018 | $150M | Series D | – | Fresenius Medical Care | – |
| Feb 2018 | $75M | Series C | – | – | – |
| Oct 2017 | $17.5M | Grant | – | – | |
| Sep 2017 | $650,000 | Grant | – | – | |
| Jul 2016 | $9.9M | Grant | – | – | |
| Oct 2015 | $150M | Series B | – | Access Industries | |
| Sep 2011 | $1.19M | Grant | – | – | |
| Feb 2010 | $236,549 | Grant | – | – | |
| Oct 2007 | $49.76M | Series B | – | – | – |
13 investors in total: 12 institutional and 1 angel.
Investors in Humacyte
Humacyte has secured backing from 13 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include SVB, Bangkok Bank and Fresenius Medical Care.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment and holding company controlled by Len Blavatnik | – | accessindustries.com | New York, United States | |
- | – | reignwood.com | - | |
Biotech startups are incubated and funded in North Carolina. | 1984 | ncbiotech.org | Durham, United States | |
Products and services for chronic kidney failure patients are developed. | 1996 | freseniusmedicalcare.com | Bad Homburg, Germany | |
- | – | cirm.ca.gov | - | |
Military forces are provided by the U.S. Department of Defense for national security. | – | defense.gov | Washington, D.C., United States | |
Medical technologies are advanced for military and civilian health. | – | mtec-sc.org | - | |
Commercial banking services across multiple segments are provided in Thailand. | 1944 | bangkokbank.com | Bangkok, Thailand | |
Offers investment strategies and management for retail and institutional clients. | 1976 | eagleasset.com | St Petersburg, United States | |
A real estate investment firm specializing in properties across San Francisco. | 1992 | pacificeagleholdings.com | San Francisco, United States |
Investor details for Humacyte
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Humacyte
45 people are tracked at Humacyte (24 in leadership, 11 in board & advisors, 10 in team); the tracked headcount is 220.
| Name | Role | Group |
|---|---|---|
Laura E. Niklason | Founder, President & CEO | Leadership |
Dale Sander | CFO, Chief Corporate Development Officer & Treasurer | Leadership |
BJ Scheessele | Chief Commercial Officer | Leadership |
Fulton Velez | Head, Field Value & Market Access | Leadership |
Chiang Wong | Head Of Global Health Economics And Outcomes Research | Leadership |
Rhianna Jobe | Senior Director, Commercial Operations | Leadership |
Tony J | Vice President Marketing | Leadership |
Alison Pilgrim | Chief Medical Officer | Leadership |
Mauricio Berdugo MD MPH | Sr. Director Medical Affairs | Leadership |
Cindy Yang Cao Ph D | Chief Regulatory Officer | Leadership |
Kaleb Naegeli | Director, Cell Biology | Leadership |
Sabrina Osborne SPHR GPHR | Chief People Officer | Leadership |
Gary Morris | VP, Finance & Corporate Controller | Leadership |
Christine Wilson PHR | Executive Director Human Resources | Leadership |
Shamik Parikh | Chief Medical Officer | Leadership |
Cindy Cao | Chief Regulatory Officer | Leadership |
Manira Rayamajhi | Sr. Director Regulatory Strategy | Leadership |
Colleen Conway | Director, CMC Regulatory Affairs | Leadership |
Thomas Kozma | Senior Director Regulatory Affairs | Leadership |
Jed Leviner | Vp, Information Technology | Leadership |
25 more people are available in the full profile.
Complete people profiles for Humacyte
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Humacyte
Humacyte is a publicly listed company on the NASDAQ with ticker symbol HUMA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date27 Aug 2021
- Listed onNASDAQ: HUMA
- Listed entityHumacyte, Inc.
- Exchange sectorHealth technology
- ISINUS44486Q1031
- Share price$0.36 (-7.88% on the day) · 2026-10-13
- Market capitalisation$99.7M
- EPS (diluted, trailing year)$-0.49
- Volume (last session)12,348,172
Financials of Humacyte
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $2.0M | -$40.8M | -$100.1M |
| 2024 | – | -$148.7M | -$107.2M |
| 2023 | – | -$110.8M | -$92.3M |
| 2022 | – | -$12.0M | -$77.9M |
| 2021 | – | -$26.5M | -$74.2M |
Detailed financial statements for Humacyte
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Humacyte
4 dated milestones of Humacyte across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Humacyte is founded.
- Funding First funding round of $150K.
- Funding Latest funding round, Debt – Venture,.
- IPO Lists on the stock exchange (IPO).
Competitors of Humacyte
Humacyte has 8 listed competitors in our database, 6 of them funded. They include CUTISS, Solsys Medical, Heartseed, ORTHOCON and Tissue Regenix, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cutiss.swiss | 2017 | Zurich, Switzerland | $94.37M | – | Personalized skin tissue therapy is developed by CUTISS for surgeries. | |
| solsysmedical.com | 1999 | Norfolk, United States | $29.55M | – | Human skin allografts and dressings for wound care are supplied. | |
| heartseed.jp | 2015 | Shinjuku, Japan | $76.73M | – | Developer of myocardial regenerative medicine for treating heart diseases | |
| orthocon.com | 2005 | Irvington, United States | $27.16M | – | Resorbable hemostatic bone putty is developed to stop surgical bleeding. | |
| tissueregenix.com | 2006 | Swillington, United Kingdom | – | 7 | Developer of regenerative medical devices by using cell technology | |
| biomimetics.com | 2000 | Franklin, United States | – | 58 | Regenerative therapeutics for musculoskeletal injuries are developed and commercialized. | |
| acera-surgical.com | 2013 | St. Louis, United States | $6.32M | – | Synthetic electrospun scaffolds are provided for regenerative medical uses. | |
| triadls.com | 2017 | Memphis, United States | $32.16M | – | Regenerative medicine technologies for wound care and orthopedics are developed. |
Detailed competitors of Humacyte
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Humacyte
The website of Humacyte (humacyte.com) receives about 11.9K visits a month and ranks #2,300,987 among all websites worldwide, #3,152 in Biotechnology and Pharmaceuticals.
- Monthly visits11.9K
▲ 30.8% vs previous month
- Unique visitors3.8K
per month
- Global rank#2,300,987
among all websites
- Category rank#3,152
Health · Biotechnology and Pharmaceuticals
- Bounce rate40%
- Pages per visit2.0
- Average visit1 min 14 sec
- DevicesDesktop 25% · Mobile 75%
Top companies in Transplant Medicine
10 companies that operate in the same segment as Humacyte (Transplant Medicine), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medical solutions for transplant patients are developed and provided. | 1998 | Brisbane, California, United States | USD 138.21 M | USD 379.81 M | 650 | |
Developer of organ transplantation technology | 1998 | Andover, Massachusetts, United States | USD 265.55 M | USD 605.49 M | 728 | |
Warm storage and transport systems for harvested organs are provided. | 2008 | Oxford, Oxfordshire, United Kingdom | USD 45.42 M | USD 1.36 M | 14 | |
Next-generation medicines for CNS and immunological disorders are developed. | 2007 | New York, New York, United States | USD 4.45 M | USD 13.11 M | 81 | |
Breakthrough therapies are developed for blood diseases and infections. | 2014 | Buffalo, New York, United States | USD 1 M | – | 22 | |
Personalized skin tissue therapy is developed by CUTISS for surgeries. | 2017 | Zurich, Switzerland | USD 94.37 M | – | – | |
Game currency trading services are provided by Magenta Piman. | 2016 | Cambridge, Massachusetts, United States | USD 150.5 M | – | 75 | |
T regulatory cell therapies are developed for immunological diseases. | 2019 | London, England, United Kingdom | USD 344.25 M | – | – | |
Therapeutics for transplantation in autoimmune and neurodegenerative diseases are developed. | 2004 | Irvine, California, United States | USD 1.89 M | – | 31 | |
Stem cell therapies are developed for treating multiple diseases. | 2021 | Natick, Massachusetts, United States | USD 181.83 M | – | 53 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Humacyte
Complete news archive for Humacyte
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Humacyte
Humacyte was founded in 2004 and raised its 1st funding round 2 years after it was founded.
Humacyte is headquartered in Morrisville, United States.
Humacyte is a funded company, having raised a total of $424.76M across 11 funding rounds to date. The company's 1st funding round was a Series B of $49.76M, raised on Jun 2006.
Humacyte has 220 employees.
Annual revenue of Humacyte is $2.04M as on Dec 31, 2025.
Humacyte is engaged in the development and manufacture of bioengineered human tissues and organs. These tissues are designed to be universally implantable, off-the-shelf, and regenerative, targeting a wide range of diseases, injuries, and chronic conditions. The companys platform supports tissue repair and replacement across various clinical needs, including vascular trauma, hemodialysis access, and investigational applications like tracheal and esophageal replacement. Solutions are built on the Acellular Tissue Engineered Vessel platform, aiming for low infection rates and broad patient accessibility in the healthcare sector.
Humacyte's top competitors include CUTISS, Acera Surgical and Heartseed.
Humacyte offers Symvess™ and Acellular Tissue Engineered Vessel (ATEV™).
Yes, Humacyte is publicly traded on NASDAQ under the ticker symbol HUMA.
Humacyte has 13 investors. Key investors include SVB, Bangkok Bank, Fresenius Medical Care, HHS, and NCBiotech.
Humacyte operates through Humacyte Global, Inc..